AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02148445 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extended Nicotine Replacement Therapy
Description: Participants in the guided maintenance therapy (GMT) arm will receive counseling focused on medication adherence and smoking reduction plus up to 52 weeks of combination nicotine replacement therapy (NRT) (nicotine patch plus choice of gum or lozenge) regardless of their interest in quitting.
Study NCT02148445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy
Study NCT02148445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine replacement therapy
Study NCT02126384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pneumovax vaccination
Description: vaccination
Study NCT02417311 — intervention group
Intervention type: OTHER
Intervention: Skin biopsy, genotyping and disease phenotyping
Description: Major steps of the project are (i) in depths clinical phenotyping and follow-up of the clinical course of probands (ii) genotyping of candidate genes involved in heart disease development and (iii) in vitro functional tests of engineered heart tissue (EHT), miniature beating heart muscles. These EHTs are generated from hiPSC (human induced pluripotent stem cells) lines derived from skin biopsies of each participant.
Study NCT00553059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: palonosetron hydrochloride
Description: 0.25 mg IV 30 minutes prior to administration of chemotherapy
Study NCT01020526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: Oral capsule 75-450 mg/day
Study NCT01363063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine
Description: One dose of 15 mg ketorolac tromethamine with a lidocaine hydrochloride free formulation in one nostril and one dose of 15 mg ketorolac tromethamine containing 6% lidocaine hydrochloride in the other nostril
Study NCT01363063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine
Description: One dose of 15 mg ketorolac tromethamine containing 0% lidocaine hydrochloride into one nostril and either placebo or a single intranasal dose of 15 mg Ketorolac tromethamine containing 0%, 4% or 6% lidocaine hydrochloride into the other nostril
Study NCT02111122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Oxybate
Study NCT02111122 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04581876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raltitrexed for injection
Description: Patients receive raltitrexed 2mg/m2 (iv, 15min) on day 1 and day 15, q4w. Treatment repeats every 4 weeks until the disease recurrence or unacceptable toxicity, death or begin a novel treatment.
Study NCT04581876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: Patients receive nab-paclitaxel at 125 mg/m2 on day 1 and day 15, q4w. Treatment repeats every 4 weeks until the disease recurrence or unacceptable toxicity, death or begin a novel treatment.
Study NCT00823381 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: resveratrol
Description: one pill of resveratrol (Resvida™) 75 mg once a day with breakfast
Study NCT00823381 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one placebo pill taken once a day with breakfast
Study NCT00823381 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Calorie Restriction
Description: supervised calorie restriction diet: 30% reduction in caloric intake
Study NCT01772355 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: semi automated core needle biopsy of orbital tumors
Study NCT05340192 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Octreotide 1 MG/ML
Description: 100 mcg (1 ml) of Octreotide
Study NCT00553059 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: 1 tablet by mouth three times a day beginning 30 minutes before chemotherapy
Study NCT03614091 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: 20 ml Bupivacaine 0.5% below erector spinae muscle groups
Study NCT03614091 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paravertebral plane block
Description: 20 ml Bupivacaine 0.5% between pleura and costotransverse ligament
Study NCT02196194 — intervention group
Intervention type: DRUG
Intervention: Tiotropium
Study NCT02260167 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A mix of natural treatments and medications
Study NCT04581395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: succinylcholine 1 minute after rocuronium pretreatment
Description: 0.05 mg/kg up to 5 mg of rocuronium pretreatment followed by 1.0 mg/kg succinlycholine t = 1 min +/- 10 sec after pretreatment
Study NCT04581395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: succinylcholine 2 minutes following rocuronium pretreatment
Description: 0.05 mg/kg up to 5 mg of rocuronium pretreatment followed by 1.0 mg/kg succinlycholine t = 2 min +/- 10 sec after pretreatment.
Study NCT00761904 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Free Generic Samples (hydrochlorothiazide, simvastatin)
Description: Free samples of generic hydrochlorothiazide (12.5 mg tabs) and simvastatin (20 mg tabs)
Study NCT00934921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: 1 x 8 mg Orally Disintegrating Tablet
Study NCT00934921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zofran®
Description: 1 x 8 mg ODT
Study NCT01188967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK598809
Description: Oral dose of 60 mg/day for a treatment period six weeks
Study NCT01188967 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02587910 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Melanole for GERD treatment
Description: Melanole is given orally as 2 capsules TID 5 minutes before each meal
Study NCT02587910 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is given orally as 2 capsules TID 5 minutes before each meal
Study NCT01171430 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole Body Dynamic Contrast Enhanced MRI (WB-DCE-MRI)
Description: 3 Whole Body Dynamic Contrast Enhanced MRI:~* 1 WB-DCE-MRI before induction of chemotherapy(initial MRI).~* 1 WB-DCE-MRI after induction high dose therapy and before intensification of chemotherapy and auto-transplant of hematopoietic sterns cells (early MRI).~* 1 WB-DCE-MRI 3 months after treatment whatever (amendment n°3) (delayed MRI).
Study NCT02846584 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 or CD20 CAR T cells briging HSCT
Description: Patients will receive a one-week regimen of chemotherapy consisting of fluid arabise and cyclophosphamide aimed to deplete the lymphocytes. One week later, patients are intravenously infused autologous anti-CD19 or anti-CD20 CAR T cells.
Study NCT03190590 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS-NeuroConn.
Description: tDCS is delivered noninvasively via electrodes applied to the surface of the head, and a mild electrical current is given during motor training.
Study NCT03190590 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TMS - Magstim.
Description: TMS is delivered noninvasively via a hand-held coil applied to the surface of the head, and a magnetic pulse probes cortical circuitry \[this is not repetitive TMS and so does NOT modulate brain excitability
Study NCT03190590 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham tDCS
Description: delivered by briefly turning on and off the stimulator at the beginning of training, which mimics the sensation of true stimulation.
Study NCT03095885 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Test Meal
Study NCT02609204 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diopsys NOVA
Description: Healthy Controls will have both eyes tested by the Diopsys NOVA machine using Pattern Electroretinogram (PERG) and Flash Electroretinogram (FERG) modules.
Study NCT03689530 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Support
Description: Participants will be paired with a peer supporter. They will meet in person one time and then be in contact by phone or texting on a weekly basis for the first 6 months of a year.~During the final six months of the year, the peer supporter and participant will be in touch at least monthly. The peer supporter will help link participants to existing health system and community diabetes prevention programs, support their engagement in formal programs, maintain achieved gains, and support participants to initiate and sustain healthy behaviors to prevent diabetes.~The 95 peer supporters who consented to participate in the study are included in this arm, along with the participants who were randomized to this arm, in the participant flow. The peer supporters were not randomized to the arm; rather, they consented to deliver the intervention. Although 95 consented, only 68 met with at least one peer, the first step in intervention delivery.
Study NCT03689530 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Participants will receive brief education and folder of information and resources.
Study NCT04792320 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Active bamboo charcoal
Description: 4g particle
Study NCT04792320 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotics
Description: 0.8g powder
Study NCT00699569 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: hyperimmune colostrum
Description: hyperimmune colostrum
Study NCT00699569 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00536679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK163090 capsule, fasted
Description: GSK163090 will be available as 1 mg hard gelatine white/white opaque capsules. Each subject will receive a single, oral dose of the study medication on the morning of Day 1. The study drug will be administered with approximately 240 milliliters (mL) of water.
Study NCT01155869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depot naltrexone
Description: Depot naltrexone 380 mg. IM monthly
Study NCT01155869 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Naltrexone
Description: Naltrexone 50 mg tablet PO daily
Study NCT04434755 — intervention group
Intervention type: OTHER
Intervention: health care professionals' exposure to bioethical issues
Description: health care professionals were differentiated considering the work context and the type of patients cured
Study NCT01756287 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Chinese ocular exercise
Description: A kind of massage around the acupuncture points around the eye.
Study NCT01756287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chinese ocular exercise
Description: A kind of massage around the acupuncture points around the eye.
Study NCT05803330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abandonment of intravenous volume expansion during preoperative preparation in patients with pheochromocytoma
Description: Abandonment of intravenous volume expansion with alpha-blockers during preoperative preparation in patients with pheochromocytoma
Study NCT03396913 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IPL
Description: Intense pulsed light (IPL) is a non-invasive and non-laser light treatment that is FDA-approved for various conditions in dermatology. Subjects will receive a total of 4 IPL treatments over the course of the study, at intervals of 2 weeks. Each treatment will include applications of 10-15 IPL pulses in the malar region and close to the lower eyelids, followed by meibomian gland expression.
Study NCT03396913 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham IPL
Description: Sham intense pulsed light (IPL) will be implemented with an IPL device in which all light is blocked by a filter. Subjects will receive a total of 4 sham treatments over the course of the study, at intervals of 2 weeks. Each treatment will include applications of10-15 sham pulses in the malar region and close to the lower eyelids, followed by meibomian gland expression.
Study NCT03396913 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MGX
Description: Meibomian gland expression (MGX) will be implemented by squeezing the meibomian glands with the aid of two Q-tips positioned on either side of the meibomian glands, or with a meibomian gland expressor forceps
Study NCT03396913 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: MGX
Description: Meibomian gland expression (MGX) will be implemented by squeezing the meibomian glands with the aid of two Q-tips positioned on either side of the meibomian glands, or with a meibomian gland expressor forceps
Study NCT04005313 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vibroacoustic device
Description: the participants will receive the vibroacustic device or music therapy
Study NCT02884583 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary function test
Description: Patients hospitalized for OFC realise a Resting pulmonary function tests (PFT) which include the assessment of ventilatory capacity: spirometry (forced expiratory flows and mobilisable volumes) and static volume assessment, by using body plethysmography, were realized before, during and after the OFC. An exhaled fraction of NO (FeNO) is also realized to characterize asthma.
Study NCT01609894 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Individualized fortification of breast milk
Description: Lactose, fat and protein content will be measured prior to breast milk fortification.~Subsequently, breast milk for preterm infants will individually fortified adjusted by using data from milk analysis.
Study NCT01609894 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Routine fortification of breast milk
Description: Infants will be fed routine fortified breast milk.
Study NCT03910478 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBS Self-Collection Kit
Description: Kit for self-collection of Dried Blood Spot (DBS) samples
Study NCT03910478 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Control Strategy
Description: Standard of care with office-based testing.
Study NCT02784704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eravacycline
Study NCT02784704 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Study NCT02784704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02784704 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT02373228 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Audio signal processing (applied offline before playback)
Study NCT03028363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olumacostat Glasaretil Gel, 5.0%
Description: Gel containing Olumacostat Glasaretil
Study NCT03028363 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Olumacostat Glasaretil Gel, Vehicle
Description: Vehicle (placebo) gel
Study NCT01300832 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Duplex scan of lower extremities
Description: Lower extremities will be duplex scanned pre and post-operatively
Study NCT05506098 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT00189475 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Study NCT00189475 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01728246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol/Paracetamol (APAP)
Description: Celecoxib 200 milligram (mg) once daily for 4 weeks and fixed dose combination of Tramadol 37.5 mg/Paracetamol 325 mg thrice daily for 4 weeks as add-on therapy.
Study NCT01728246 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non-Tramadol/APAP
Description: Celecoxib 200 mg alone once daily for 4 weeks.
Study NCT04962516 — intervention group
Intervention type: DEVICE
Intervention: single-use precision filtered infusion sets
Description: single-use precision filter infusion set (Dalian JMS Medical Apparatus Co., Ltd.)
Study NCT04962516 — intervention group
Intervention type: DEVICE
Intervention: single-use precision filter infusion set with needle
Description: single-use precision filter infusion set with needle (Shandong Zhongbao Kang Medical Apparatus Co., Ltd.)
Study NCT03633006 — intervention group
Intervention type: OTHER
Intervention: Blood Sample Collection
Description: Subjects participating in the study will have blood drawn at enrollment. Additional blood samples may be collected at 12 months from enrollment.
Study NCT03633006 — intervention group
Intervention type: OTHER
Intervention: Blood Sample Collection
Description: Subjects participating in the study will have blood drawn at enrollment. Additional blood samples may be collected at 12 months from enrollment if lung cancer has not been confirmed.
Study NCT03633006 — intervention group
Intervention type: OTHER
Intervention: Blood Sample Collection
Description: Subjects participating in the study will have blood drawn at enrollment.
Study NCT01924819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin + cisplatin + 5-fluorouracil OR epirubicin + cisplatin + capecitabine OR epirubicin + oxaliplatin + capecitabine OR 5-Fluorouracil + leucovorin + oxaliplatin + docetaxel
Description: Epirubicin 50 mg/m2 IV day 1, cisplatin 60 mg/m2 IV day 1, 5-fluorouracil 200 mg/m2/d IV 21 day continuous infusion (ECF chemotherapy).~Epirubicin 50 mg/m2 IV day 1, Cisplatin 60 mg/m2 IV day 1, Capecitabine (X = Xeloda) 625mg/m2, bid days 1-21 (ECX chemotherapy)~Epirubicin 50mg/m2 IV day 1, Oxaliplatin (O) 130mg/m2 IV day 1, Capecitabine 625mg/m2, bid days 1-21 (EOX chemotherapy)~5-Fluorouracil 2600 mg/m² IV 24 h infusion day 1, Leucovorin (L) 200 mg/m² IV day 1, Oxaliplatin 85 mg/m² IV day 1, Docetaxel (T) 50 mg/m² IV day 1 (FLOT chemotherapy)
Study NCT01924819 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin + cisplatin + 5-fluorouracil OR epirubicin + cisplatin + capecitabine OR epirubicin + oxaliplatin + capecitabine OR 5-Fluorouracil + leucovorin + oxaliplatin + docetaxel
Description: Epirubicin 50 mg/m2 IV day 1, cisplatin 60 mg/m2 IV day 1, 5-fluorouracil 200 mg/m2/d IV 21 day continuous infusion (ECF chemotherapy).~Epirubicin 50 mg/m2 IV day 1, Cisplatin 60 mg/m2 IV day 1, Capecitabine (X = Xeloda) 625mg/m2, bid days 1-21 (ECX chemotherapy)~Epirubicin 50mg/m2 IV day 1, Oxaliplatin (O) 130mg/m2 IV day 1, Capecitabine 625mg/m2, bid days 1-21 (EOX chemotherapy)~5-Fluorouracil 2600 mg/m² IV 24 h infusion day 1, Leucovorin (L) 200 mg/m² IV day 1, Oxaliplatin 85 mg/m² IV day 1, Docetaxel (T) 50 mg/m² IV day 1 (FLOT chemotherapy)
Study NCT01924819 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy
Description: Chemotherapy: Continuous infusional 5-fluorouracil 200mg/m2/day, 7 days per week, throughout the entire period of radiotherapy or capecitabine 825 mg/m2, oral tablet twice daily, days 1-5 of each week of radiotherapy (without weekends).~Radiotherapy: 45 Gy of radiation in 25 fractions, five days per week for five weeks.
Study NCT01924819 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastric resection
Description: The acceptable resections are a total gastrectomy, a subtotal gastrectomy, and an esophagogastrectomy (Ivor-Lewis esophagogastrectomy for gastroesophageal junction cancers \[Siewert Type II and Siewert Type III\] invading up to but no more than 2cm of the lower esophagus). The minimum extent of the operation should be a D1+ lymph node dissection but it is recommended that a D2 dissection be performed or a D1+ for gastroesophageal junction cancers requiring an esophagogastrectomy.
Study NCT01924819 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric resection
Description: The acceptable resections are a total gastrectomy, a subtotal gastrectomy, and an esophagogastrectomy (Ivor-Lewis esophagogastrectomy for gastroesophageal junction cancers \[Siewert Type II and Siewert Type III\] invading up to but no more than 2cm of the lower esophagus). The minimum extent of the operation should be a D1+ lymph node dissection but it is recommended that a D2 dissection be performed or a D1+ for gastroesophageal junction cancers requiring an esophagogastrectomy.
Study NCT06116097 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition education
Description: Fifty participants took 6 physical nutrition education lectures and the other group (n=33) didn't have any nutrition education. Nutrition education was comprimised of 6 physical face to face 60 minutes sessions which was given every week in a school class. Each session was consisted of a different subject including energy metabolism in sport, energy balance, nutrition before and after training, low energy availability, macro and micronutrients, hydration and supplements. Participants also got written information as a printed booklet in order to be able to take notes under sessions and review after the sessions.
Study NCT03469895 — intervention group
Intervention type: DRUG
Intervention: ibrutinib ou idelalisib
Description: treatment by ibrutinib or idelalisib for autoimmune cytopenia
Study NCT04161924 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: X-ray imaging with physical grid using conventional processing
Description: X-ray imaging with physical grid using conventional processing